Olema Pharmaceuticals, Inc.
OLMAAs of the close on Sep 25, 2026
Price
$8.75
Market cap
—
The cover-page share count does not match the latest report's share count
P/E (diluted TTM)
—
The fourth quarter's per-share figure could not be confirmed from the annual report
EPS (TTM)
—
The fourth quarter's per-share figure could not be confirmed from the annual report
Dividend yield
—
Dividend records do not yet cover the latest payments
Figures shown here come from public SEC filings. Dates beside each section show the available history.
How Olema Pharmaceuticals, Inc. Makes Money
No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 7 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 23, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| OSAIC HOLDINGS, INC. | 2026-03-31 | 317 | Not shown | SEC filing |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2026-03-31 | 275,000 | Not shown | SEC filing |
| CITIGROUP INC | 2026-03-31 | 27,578 | Not shown | SEC filing |
| LPL Financial LLC | 2026-03-31 | 57,405 | Not shown | SEC filing |
| SEB Asset Management AB | 2026-03-31 | 339,461 | Not shown | SEC filing |
| Mirae Asset Global Investments Co., Ltd. | 2026-03-31 | 4,181 | Not shown | SEC filing |
| State of New Jersey Common Pension Fund D | 2026-03-31 | 12,901 | Not shown | SEC filing |
| JANUS HENDERSON GROUP PLC | 2026-03-31 | 7,108,488 | Not shown | SEC filing |
| AXQ CAPITAL, LP | 2026-03-31 | 14,633 | Not shown | SEC filing |
| ALPS ADVISORS INC | 2026-03-31 | 64,035 | Not shown | SEC filing |
| Tema ETFs LLC | 2026-03-31 | 79,243 | Not shown | SEC filing |
| Police & Firemen's Retirement System of New Jersey | 2026-03-31 | 19,191 | Not shown | SEC filing |
| Optimize Financial Inc | 2026-03-31 | 20,567 | Not shown | SEC filing |
| Rockefeller Capital Management L.P. | 2026-03-31 | 746 | Not shown | SEC filing |
| Inscription Capital, LLC | 2026-03-31 | 15,273 | Not shown | SEC filing |
| Pictet Asset Management Holding SA | 2026-03-31 | 217,023 | Not shown | SEC filing |
| PDT Partners, LLC | 2026-03-31 | 15,301 | Not shown | SEC filing |
| Headlands Technologies LLC | 2026-03-31 | 59,374 | Not shown | SEC filing |
| SIMPLEX TRADING, LLC | 2026-03-31 | 11,127 | Not shown | SEC filing |
| FIDEURAM - INTESA SANPAOLO PRIVATE BANKING S.P.A. | 2026-03-31 | 116,812 | Not shown | SEC filing |
- Each value is checked against Olema Pharmaceuticals, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 20 rows: the value per share could not be confirmed against the share prices on file from within three months of the report date.
120 filers have only one report here.
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-03-04 | Mitchell Shawnte · CHIEF LEGAL OFFICER | Common Stock | S — Open market or private sale | −24,767 | 24.25 | SEC filing |
| 2026-03-04 | Mitchell Shawnte · CHIEF LEGAL OFFICER | Comon Stock | S — Open market or private sale | −233 | 24.69 | SEC filing |
| 2026-03-03 | Mitchell Shawnte · CHIEF LEGAL OFFICER | Common Stock | S — Open market or private sale | −15,000 | 23.01 | SEC filing |
| 2026-01-20 | Harmon Cyrus · Director | Common Stock | S — Open market or private sale | −10,000 | 26.88 | SEC filing |
| 2026-01-15 | Kovacs Shane William Charles · CH. OPERATING & FINANCIAL OFF. | Common Stock | S — Open market or private sale | −100,000 | 28.73 | SEC filing |
| 2026-01-14 | Harmon Cyrus · Director | Common Stock | S — Open market or private sale | −3,489 | 29.12 | SEC filing |
| 2026-01-14 | Myles David C. · CH. DISCOV. & NON-CLIN DEV OFF | Common Stock | S — Open market or private sale | −35,003 | 28.99 | SEC filing |
| 2026-01-14 | Myles David C. · CH. DISCOV. & NON-CLIN DEV OFF | Common Stock | S — Open market or private sale | −14,997 | 28.60 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-18 | Garland J. Scott · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +29,500 | SEC filing |
| 2026-06-18 | Raman Prakash · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +29,500 | SEC filing |
| 2026-06-18 | Graham G. Walmsley · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +29,500 | SEC filing |
| 2026-06-18 | BUTITTA CYNTHIA M · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +29,500 | SEC filing |
| 2026-06-18 | CLARK IAN T · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +29,500 | SEC filing |
| 2026-06-18 | RAPPAPORT ANDREW · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +29,500 | SEC filing |
| 2026-06-18 | Hrustanovic Gorjan · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +29,500 | SEC filing |
| 2026-06-18 | BIOTECHNOLOGY VALUE FUND L P · Director, other | Stock Option (Right to buy) | A — Grant, award, or other acquisition | +29,500 | SEC filing |
Showing 8 of 25 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2025-01-10 | Bain Capital Life Sciences Investors, LLC · 10% owner | Pre-Funded Warrant (right to buy) | J — Other acquisition or disposition | +3,500,000 | SEC filing |
| 2025-01-10 | BIOTECHNOLOGY VALUE FUND L P · Director, other | Common stock, $0.0001 par value | D — Disposition to the issuer | −161,810 | SEC filing |
| 2025-01-10 | BIOTECHNOLOGY VALUE FUND L P · Director, other | Common stock, $0.0001 par value | D — Disposition to the issuer | −235,450 | SEC filing |
| 2025-01-10 | Bain Capital Life Sciences Investors, LLC · 10% owner | Common Stock | J — Other acquisition or disposition | −3,500,000 | SEC filing |
| 2025-01-10 | BIOTECHNOLOGY VALUE FUND L P · Director, other | Common stock, $0.0001 par value | D — Disposition to the issuer | −22,740 | SEC filing |
| 2024-12-04 | BIOTECHNOLOGY VALUE FUND L P · Director, other | Common stock, $0.0001 par value | D — Disposition to the issuer | −153,441 | SEC filing |
| 2024-12-04 | BIOTECHNOLOGY VALUE FUND L P · Director, other | Common stock, $0.0001 par value | D — Disposition to the issuer | −1,418,736 | SEC filing |
| 2024-12-04 | BIOTECHNOLOGY VALUE FUND L P · Director, other | Common stock, $0.0001 par value | D — Disposition to the issuer | −1,797,527 | SEC filing |
Showing 8 of 10 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.